The DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Open accessAbstract
Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a complex consisting of YAP, TAZ, TEADs, and AP-1 (dimer of cFos and transcription factor Jun [JUN] families) was found to synergistically regulate the transcription of target genes (35–37).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have demonstrated that activated Yap, through genetic amplification of YAP- or WNT5a-mediated dysregulation of the Hippo pathway, enables bypass of Kras suppression in Kras-driven murine pancreatic cancer and lung cancer models (37–39).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“YAP, a pivotal EMT regulator gene, can restore oncogenicity in murine tumors that have lost KRAS [54,131].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies using inducible suppression of KRAS via RNA interference or genetically engineered inducible KrasG12D alleles (i.e., “iKras” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRASG12D suppression (35–38).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using a genetically engineered mouse (GEM) model of PDAC driven by inducible KRASG12D, we recently demonstrated that activation of the YAP1 oncogene drives resistance to genetic inactivation of KRAS∗, a finding further confirmed in KRAS∗-driven colorectal cancer (CRC).”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The YAP1 oncogene has been well established as one of the major drivers of bypassing oncogene addiction and promoting acquired resistance to targeted therapies in several cancer types, including pancreatic cancer, lung cancer, colorectal cancer, melanoma, and glioblastoma.9,10,38,39,40”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“In the context of pancreatic cancer, KRAS dependency can be by-passed by the elevated expression of the transcription factor YAP1, which promotes EMT and confers cell-intrinsic resistance to KRAS loss (84, 85).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [84]
In the citing paper
“On the one hand, it is known that YAP activity is positively correlated with the resistance to therapies targeting KRAS signaling components including RAF and MEK,[ 28, 46 ] and YAP is required for KRAS‐dependent cell transformation: extracellular supplementation of YAP activators can rescue cancer cell killing after KRAS knockdown.[ 47 ]”
From Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
TopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L. S., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,682
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Self-citationTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases
Karin, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16483 · Cited by 2,423
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citation
Flagged first, then by citations
1 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 753
Liu, J., Bai, W., Zhou, T., Xie, Y., Yang, B., Sun, J., Wang, Y., Li, X., Hou, X., Liu, Z., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327492 · Cited by 42
FRA-1 as a Regulator of EMT and Metastasis in Breast Cancer
Casalino, L., Talotta, F., Matino, I., & Verde, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098307 · Cited by 45
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
Ischenko, I., Petrenko, O., & Hayman, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4538 · Cited by 42
Chen, Q., Song, S., Wei, S., Liu, B., Honjo, S., Scott, A. W., Jin, J., Ma, L., Zhu, H., Skinner, H. D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4540 · Cited by 42
Nussinov, R., Tsai, C., Muratcioğlu, S., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1100079 · Cited by 42
Ashok, G., Miryala, S. K., Saju, M. T., Anbarasu, A., & Ramaiah, S. (2022) · Molecular Genetics and Genomics · doi:10.1007/s00438-022-01943-w · Cited by 41
Nguyen, T., Andrējeva, D., Gupta, R., Choudhary, C., Hong, X., Eichhorn, P. J. A., Loya, A. C., & Cohen, S. M. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.1 · Cited by 41
MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway
Alam, M., Bouillez, A., Tagde, A., Ahmad, R., Rajabi, H. N., Maeda, T., Hiraki, M., Suzuki, Y., & Kufe, D. W. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0233 · Cited by 41
Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway
Zhang, Y., Zhou, M., Wei, H., Zhou, H., He, J., Lu, Y., Wang, D., Chen, B., Zeng, J., Peng, W., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3896 · Cited by 41
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 47
Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia
Li, J., Dai, Y., Wu, L., Zhang, M., Ouyang, W., Huang, J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-020-0821-6 · Cited by 44
Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma
Saunders, J. T., Holmes, B., Benavides-Serrato, A., Kumar, S., Nishimura, R. N., & Gera, J. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03699-6 · Cited by 43
YAP/TAZ signalling in colorectal cancer: lessons from consensus molecular subtypes
Mouillet-Richard, S., & Laurent-Puig, P. (2020) · Cancers · doi:10.3390/cancers12113160 · Cited by 40
Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers
Liang, H., Xu, Y., Zhao, J., Chen, M., & Wang, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00761-z · Cited by 45
Mohamed, A. D., Sun, C., Mello, V. D., Selfe, J., Missiaglia, E., SHIPLEY, J. M., Murray, G. I., Zammit, P. S., & Wackerhage, H. (2016) · The Journal of Pathology · doi:10.1002/path.4745 · Cited by 44
Poorly Differentiated Clusters: Clinical Impact in Colorectal Cancer
Barresi, V., Bonetti, L. R., Ieni, A., Caruso, R. A., & Tuccari, G. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.06.002 · Cited by 40
CRISPR-Cas9: from Genome Editing to Cancer Research
Chen, S., Sun, H., Miao, K., & Deng, C. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.17421 · Cited by 40
The cell polarity protein Scrib functions as a tumor suppressor in liver cancer
Kapil, S., Sharma, B. K., Patil, M., Elattar, S., Yuan, J., Hou, X. S., Kolhe, R. B., & Ande, S. (2017) · Oncotarget · doi:10.18632/oncotarget.15713 · Cited by 46
Emerging role of Hippo signalling pathway in bladder cancer
Xia, J., Zeng, M., Zhu, H., Chen, X., Weng, Z., & Li, S. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13293 · Cited by 42
Clinical significance of YAP1 activation in head and neck squamous cell carcinoma
Eun, Y., Lee, D.-J., Lee, Y.-C., Sohn, B., Kim, E., Yim, S. Y., Kwon, K., & Lee, J.-S. (2017) · OncoTarget · doi:10.18632/oncotarget.22666 · Cited by 38
Dynamic PEG–Peptide Hydrogels via Visible Light and FMN‐Induced Tyrosine Dimerization
Liu, H., Nguyen, H. D., & Lin, C. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800954 · Cited by 40
The potential role of YAP in head and neck squamous cell carcinoma
Shin, E., & Kim, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00492-9 · Cited by 42
Self-citationVučetić, M., Daher, B., Cassim, S., Meira, W., & Pouysségur, J. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02994-w · Cited by 40
Zhou, W., Shen, Q., Wang, H., Yang, J., Zhang, C., Deng, Z., Wu, K., Zhou, Y., Zeng, J., Zhang, Y., et al. (2020) · Journal of Immunology Research · doi:10.1155/2020/9510594 · Cited by 40
Tang, Y., & Fan, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-12776-8 · Cited by 40
Organ Size Control Is Dominant over Rb Family Inactivation to Restrict Proliferation In Vivo
Ehmer, U., Zmoos, A., Auerbach, R. K., Vaka, D., Butte, A. J., Kay, M. A., & Sage, J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.025 · Cited by 40
Hsu, P., Yang, C., Jablons, D. M., & You, L. (2018) · Biomedicines · doi:10.3390/biomedicines6040114 · Cited by 39
Chai, Y., Xiang, K., Wu, Y., Zhang, T., Liu, Y., Liu, X., Zhen, W., & Si, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.911594 · Cited by 39
RetractedContext-dependent transcriptional regulations of YAP/TAZ in cancer
Guo, Y., Luo, J., Zou, H., Liu, C., Deng, L., & Li, P. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.019 · Cited by 40
Wu, Q., Li, J., Sun, S., Chen, X., Zhang, H., Li, B., & Sun, S. (2017) · Bioscience Reports · doi:10.1042/bsr20171072 · Cited by 38
Barresi, V., Bonetti, L. R., & Bettelli, S. R. (2015) · Pathology · doi:10.1097/pat.0000000000000300 · Cited by 38
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 40
Regulation of Hippo signaling pathway in cancer: A MicroRNA perspective
Samji, P., Rajendran, M. K., Warrier, V. P., Ganesh, A., & Karunagaran, D. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109858 · Cited by 40
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 41
The biology of YAP in programmed cell death
Cheng, Y., Mao, M., & Lu, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00365-5 · Cited by 42
Chakravarthy, A., Reddin, I. G., Henderson, S. R., Dong, C., Kirkwood, N. K., Jeyakumar, M., Rothschild-Rodriguez, D., Gonzalez-Martinez, N., McDermott, J. R., Su, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33544-x · Cited by 40
Johnatty, S. E., Tyrer, J. P., Kar, S., Beesley, J., Lu, Y., Gao, B., Fasching, P. A., Hein, A., Ekici, A. B., Beckmann, M. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0632 · Cited by 38
Kaller, M., & Hermeking, H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42059-2_4 · Cited by 36
The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma
Lee, H.-J., Pham, T., Chang, M. T., Barnes, D., Cai, A. G., Noubade, R., Tótpál, K., Chen, X., Tran, C., Hagenbeek, T. J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1704 · Cited by 38
Hu, L. T., Wang, J., Wang, Y., Wu, C., Wu, C., Mao, B., Prasad, E. M., Wang, Y., & Chin, Y. E. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00639-1 · Cited by 37
The Hippo signal transduction pathway in soft tissue sarcomas
Mohamed, A. D., Tremblay, A., Murray, G. I., & Wackerhage, H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.05.006 · Cited by 39
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
Lue, H.-W., Cole, B. C., Rao, S. A. M., Podolak, J., Gaest, A. V., King, C. J., Eide, C. A., Wilmot, B., Xue, C., Spellman, P. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5971 · Cited by 37
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
Chen, P., Sun, C., Wang, H., Zhao, W., Wu, Y., Guo, H., Zhou, C., & He, Y. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06053-y · Cited by 36
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej, E., Domaradzka, A., Radzka, J., Drulis‐Fajdasz, D., Kulbacka, J., & Gizak, A. (2025) · Cells · doi:10.3390/cells14060403 · Cited by 47
Zhou, H., Li, G., Huang, S., Feng, Y., & Zhou, A. (2019) · Oncology Letters · doi:10.3892/ol.2019.10387 · Cited by 36
Zheng, Y., Nie, P., & Xu, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109628 · Cited by 36
Malouf, G. G., Flippot, R., Dong, Y., DiNatale, R. G., Chen, Y., Su, X., Compérat, É., Morgan Rouprêt, A., Mano, R., Blum, K. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57534-5 · Cited by 36
An Updated Understanding of the Role of YAP in Driving Oncogenic Responses
Morciano, G., Vezzani, B., Missiroli, S., Boncompagni, C., Pinton, P., & Giorgi, C. (2021) · Cancers · doi:10.3390/cancers13123100 · Cited by 37
Oncogenic Signaling Adaptor Proteins
Luo, L. Y., & Hahn, W. C. (2015) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2015.09.001 · Cited by 39
Self-citationRao, G., Kim, I.-K., Conforti, F., Liu, J., Zhang, Y.-W., & Giaccone, G. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.013 · Cited by 34
Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma
Shi, H., Zou, Y., Zhong, W., Li, Z., Wang, X., Yin, Y., Li, D., Liu, Y., & Li, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05272-2 · Cited by 38
Self-citationFang, B. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 37
Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?
Morice, S., Danieau, G., Rédiní, F., Royer, B. B.-L., & Verrecchia, F. (2020) · Cancers · doi:10.3390/cancers12030645 · Cited by 37
Hao, Q., Zong, X., Sun, Q., Lin, Y.-C., Song, Y. J., Hashemikhabir, S., Hsu, R. Y. C., Kamran, M. Z., Chaudhary, R., Tripathi, V., et al. (2020) · eLife · doi:10.7554/elife.55102 · Cited by 35
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 39
Cho, Y., Cha, P.-H., Kaduwal, S., Park, J.-C., Lee, S. G., Yoon, J.-S., Shin, W., Kim, H., Ro, E. J., Koo, K.-H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13172 · Cited by 35
Parsana, P., Amend, S. R., Hernandez, J. R., Pienta, K. J., & Battle, A. J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3413-3 · Cited by 33
YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth
Jiang, N., Ke, B., Hjort-Jensen, K., Iglesias‐Gato, D., Wang, Z., Chang, P., Zhao, Y., Niu, X., Wu, T., Peng, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23014 · Cited by 34
Liu, X., Wang, Y., Chen, B., Chan, W. N., Mui, C. W., Cheung, A. H. K., Zhang, J., Wong, K. Y., Yu, J. Q., Kang, W., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102512 · Cited by 34
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
Hou, P., Ma, X., Yang, Z., Zhang, Q., Wu, C.-J., Li, J., Tan, L., Yao, W., Yan, L., Zhou, X., et al. (2021) · Genes & Development · doi:10.1101/gad.348787.121 · Cited by 35
Multi-Functional Regulation by YAP/TAZ Signaling Networks in Tumor Progression and Metastasis
Thrash, H. L., & Pendergast, A. M. (2023) · Cancers · doi:10.3390/cancers15194701 · Cited by 35
Weng, H., Wang, X., Li, M., Wu, X., Wang, Z., Wu, W., Zhang, Z., Zhang, Y., Zhao, S., Liu, S., et al. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1070994 · Cited by 33
Self-citationmiR-1260b is a Potential Prognostic Biomarker in Colorectal Cancer
Liu, D., Guan, Q., Gao, M., Jiang, L., & Kang, H.-X. (2016) · Medical Science Monitor · doi:10.12659/msm.898733 · Cited by 33
MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells
Xu, H., Zhou, S., Xia, H., Yu, H., Tang, Q., & Bi, F. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0309-6 · Cited by 34
Role of Hedgehog and Hippo signaling pathways in cancer: A special focus on non-coding RNAs
Sharma, U., Tuli, H. S., Uttam, V., Choudhary, R., Sharma, B., Sharma, U., Prakash, H., & Jain, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106523 · Cited by 33
MARK2/MARK3 Kinases Are Catalytic Codependencies of YAP/TAZ in Human Cancer
Klingbeil, O., Skopelitis, D. S., Tonelli, C., Yoshimoto, T., Alpsoy, A., Panepinto, M. C., Minicozzi, F., Merrill, J. R., Cafiero, A. M., Aggarwal, D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1529 · Cited by 31
Identification, functional insights and therapeutic targeting of EMT tumour states
Dong, A., & Blanpain, C. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00873-0 · Cited by 41
Hsu, P., Miao, J., Huang, Z., Yang, Y., Xu, Z., You, J., Dai, Y., Yeh, C., Chan, G., Liu, S., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13582 · Cited by 32
Loss of HACE1 promotes colorectal cancer cell migration via upregulation of YAP1
Zhou, Z., Zhang, H., Zhang, Z., Sun, H., Liu, H., Gou, X., Yu, X., & Huang, Y. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27653 · Cited by 32
Yang, J. P., Ryan, D. J., Lan, G., Zou, X., & Liu, P. (2019) · Nature Protocols · doi:10.1038/s41596-018-0096-4 · Cited by 32
Hsu, P., Tian, B., Yang, Y., Wang, Y., Liu, S., Urisman, A., Yang, C., Xu, Z., Jablons, D. M., & You, L. (2019) · Oncology Reports · doi:10.3892/or.2019.7207 · Cited by 32
LATS1/2 suppress NFκB and aberrant EMT initiation to permit pancreatic progenitor differentiation
Braitsch, C. M., Azizoglu, D. B., Htike, Y., Barlow, H. R., Schnell, U., Chaney, C. P., Carroll, T. J., Stanger, B. Z., & Cleaver, O. B. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000382 · Cited by 31
Shen, J., Huang, Q., Jia, W., Feng, S., Liu, L., Li, X., Tao, D., & Xie, D. (2021) · Oncogene · doi:10.1038/s41388-022-02344-4 · Cited by 31
H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization
Rawat, S. J., Araiza‐Olivera, D., Arias‐Romero, L. E., Cruz, O. V., Prudnikova, T. Y., Röder, H., & Chernoff, J. (2016) · Current Biology · doi:10.1016/j.cub.2016.04.027 · Cited by 32
Reggiani, F., Gobbi, G., Ciarrocchi, A., Ambrosetti, D. C., & Sancisi, V. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188341 · Cited by 33
Yang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31
“These cells were ranked according to Previous studies have demonstrated that activated Yap, through genetic amplification of YAP - or WNT5a-mediated dysregulation of the Hippo pathway, enables bypass of Kras suppression in Kras-driven murine pancreatic cancer and lung cancer models (37–39).”
Paul, S., Hagenbeek, T. J., Tremblay, J., Kameswaran, V., Ong, C. C., Liu, C., Guarnaccia, A. D., Mondo, J. A., Hsu, P., Kljavin, N. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56634-y · Cited by 34
A first-in-class EGFR-directed KRAS G12V selective inhibitor
Stanland, L. J., Huggins, H. P., Sahoo, S. S., Porrello, A., Chareddy, Y. S., Azam, S. H., Perry, J. L., Pallan, P. S., Whately, K. M., Edatt, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.05.016 · Cited by 34
RASSF5: An MST activator and tumor suppressor in vivo but opposite in vitro
Liao, T.-J., Tsai, C., Jang, H., Fushman, D., & Nussinov, R. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.09.001 · Cited by 30
Zhang, Y., Yan, S., Chen, J., Gan, C., Chen, D., Li, Y., Wen, J., Kremerskothen, J., Chen, S., Zhang, J., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13281 · Cited by 31
Li, M., Wang, X., Liao, W., Liu, J., Liao, Y., & He, Q. (2017) · Oncology Reports · doi:10.3892/or.2017.6019 · Cited by 31
Self-citationXie, W., Han, Z., Zuo, Z., Xin, D., Chen, H., Huang, J., Zhu, S., Lou, H., Yu, Z., Chen, C., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05648-9 · Cited by 30
Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells
Zhou, W. J., Lim, A., Elmadbouh, O. H. M., Edderkaoui, M., Osipov, A., Mathison, A., Urrutia, R. A., Liu, T., Wang, Q., & Pandol, S. J. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.003 · Cited by 33
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?
Paul, S., Sims, J., Pham, T., & Dey, A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.10.004 · Cited by 30
Huang, C., Xiang, Y., Chen, S., Yu, H., Wen, Z., Ye, T., Sun, H., Kong, H., Li, D., Yu, D., et al. (2017) · Cancer Science · doi:10.1111/cas.13347 · Cited by 30
Birgani, M. J. T., Teimoori, A., Ghadiri, A., Asl, H. M., Danyaei, A., & Khanbabaei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28148 · Cited by 30
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 31
Hu, X., Zhang, Y., Yu, H. N., Zhao, Y., Sun, X., Li, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012173 · Cited by 30
Nguyen, T., Kugler, J., & Cohen, S. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169587 · Cited by 30
Lü, T., Sun, L., & Zhu, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.031 · Cited by 29
Buckarma, E. H., Werneburg, N. W., Conboy, C. B., Kabashima, A., O’Brien, D. R., Wang, C., Ilyas, S. I., & Smoot, R. L. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0165 · Cited by 30
García-Rendueles, M. E. R., Krishnamoorthy, G. P., Saqcena, M., Acuña-Ruíz, A., Revilla, G., de Stanchina, E., Knauf, J. A., Lester, R., Xu, B., Ghossein, R. A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01676-9 · Cited by 29
Wang, K., Song, K., Ma, Z., Yao, Y., Liu, C., Yang, J., Xiao, H., Zhang, J., Zhang, Y., & Zhao, W. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0902-y · Cited by 30
Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis
Azad, T., Rezaei, R., Surendran, A., Singaravelu, R., Boulton, S., Dave, J., Bell, J. C., & Ilkow, C. S. (2020) · Cancers · doi:10.3390/cancers12082042 · Cited by 29
Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28
Han, Y., Yu, C.-C., Fine, S. A., Youssof, A. L., Yang, Y., Yan, J., Karg, D. C., Cheung, E. C., Friedman, R. A., Ying, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02040-9 · Cited by 28
Es, H. A., Cox, T. R., Sarafraz-Yazdi, E., Thiery, J. P., & Warkiani, M. E. (2021) · Cancers · doi:10.3390/cancers13205118 · Cited by 28
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
Ooki, A., Osumi, H., Chìn, K., Watanabe, M., & Yamaguchi, K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138377 · Cited by 28
It’s all downstream from here: RTK/Raf/MEK/ERK pathway resistance mechanisms in glioblastoma
Yakubov, R., Kaloti, R., Persaud, P., McCracken, A., Zadeh, G. M., & Bunda, S. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04930-w · Cited by 29
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 28
Metadata
- Authors
- Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., Zwang, Y., Roberts, T. M., Root, D. E., Jacks, T., & Hahn, W. C.
- Affiliations
- Broad Institute (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Jacks, Tyler
- Hahn, William C.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 158
- Issue
- 1
- Pages
- 171-184
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4110062
- OpenAlex
- W2064644124
- Cited by
- 744
- References
- 69
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 50 · 2023: 56 · 2022: 59 · 2021: 58 · 2020: 82 · 2019: 68 · 2018: 58 · 2017: 73 · 2016: 75 · 2015: 61 · 2014: 22
- FWCI
- 38.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (P30-CA14051, W81XWH)
- Howard Hughes Medical Institute
- American Association for Cancer Research
- Hope Funds for Cancer Research (HFCR-11-03-03)
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051)
- National Institutes of Health (W81XWH)
- National Cancer Institute (P50CA127003, K99CA169512, R01CA140545, CA14051, R00CA169512, P01CA050661, U01CA176058, P01CA154303, P30CA014051, P30-CA-14051)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- KRAS, YAP, oncogenic Ras, epithelial-mesenchymal transition, tumor cell survival, FOS, transcriptional coactivator, acquired drug resistance, colon cancer, lung cancer, cell transformation, transcriptional regulation
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Survival, Colonic Neoplasms, Humans, Lung Neoplasms, Phosphoproteins, Proto-Oncogene Proteins, Transcription Factors, Signal Transduction, Transcriptional Activation, Proto-Oncogene Proteins p21(ras), Drug Delivery Systems, ras Proteins, Cell Cycle Proteins, Drug Resistance, Neoplasm, HCT116 Cells, Adaptor Proteins, Signal Transducing, Mice, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
